Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

MGI sale comes less than two weeks after the biopharma said it was exploring "strategic alternatives."

Related Content

BMS & Otsuka Expand Their Abilify Deal, Enter into New Oncology Co-Promotion
Shionogi Buys Sciele: U.S. Sales Platform For Crestor Innovator
FDA Rejects Eisai’s Aquavan Injection
Eisai To Try New Dosing sNDA For Dacogen
FDA Panel Backs MGI's Aquavan - With Proviso
Takeda Reaffirms Oncology Goals With $8.8 Billion Millennium Acquisition
FDA Sets Advisory Date For MGI’s Aquavan
Spectrum’s Bone-Cancer Drug Wins FDA Nod
Investors Iron Out AMAG Ferumoxytol Doubts
Eisai’s 2008 Eribulin NDA Plan Foiled; Beat To The Punch By Bristol-Myers Squibb Drug





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts